“An initiative to protect the European pharmaceutical supply chain from the entry of falsified medicines.”
The risk of falsified medicines is growing on a global scale. As a result, the European Union has stipulated a catalogue of measures to prevent falsified medicines from entering the legal supply chain. The EU Commission has published additional technical details for the further design of security features with the Delegated Regulation (EU) 2016/161
in the Official Journal of the European Union. Starting from February 9, 2019 only prescription medicines which bear the new safety features may be put into circulation.
In order to counter the threat of falsified medicines entering the legal supply chain, the European Parliament and Council have released a Directive on Falsified Medicines (2011/62/EU)
(amending Directive 2001/83/EC). It aims at improving patient safety by mandating the Marketing Authorisation Holders and manufacturers to put a system in place that is preventing falsified medicines from entering the legal supply chain, the European Medicines Verification System. The European Medicines Verification System (EMVS) should guarantee Medicines authenticity by an end-to-end verification.